Clinical Trials
184
19 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2003
Active, not recruiting
14
7.6%
Approved For Marketing
3
1.6%
Completed
122
66.3%
No Longer Available
1
0.5%
Not yet recruiting
5
2.7%
Recruiting
16
8.7%
Terminated
13
7.1%
Unknown
1
0.5%
Withdrawn
9
4.9%
No approval data available
- Iambic Therapeutics filed an S-1 with the SEC on September 21, 2026 to list on the Nasdaq Global Select Market under the ticker IAM. - Proceeds will advance clinical development of lead HER2 inhibitor IAM1363 plus preclinical candidates IAM217 and IAM-C1, alongside general corporate purposes. - IAM1363, an oral pan-mutant brain-penetrant HER2 inhibitor, is in a Phase 1/1b basket study with a registrational trial planned as early as 2027. - The company reported $12.8 million in collaboration revenue for the six months ended June 30, 2026, against a $50.1 million net loss for the same period.
- Jazz Pharmaceuticals closed its $820 million upfront acquisition of Actio Biosciences on September 15, 2026, making Actio a wholly owned subsidiary. - The deal adds ABS-1230, an oral, selective KCNT1 inhibitor in clinical development as a potential first-in-class precision therapy for KCNT1-related epilepsy. - In an early clinical proof-of-concept trial, children with KCNT1-related epilepsy receiving ABS-1230 experienced meaningful seizure reductions, supporting further development. - ABS-1230 holds FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations and has been accepted into the agency's Rare Disease Evidence Principles process.
- Amgen's phase III DeLLphi-305 trial met its primary overall survival endpoint for tarlatamab plus durvalumab versus durvalumab alone as first-line maintenance in extensive-stage small-cell lung cancer. - The 563-patient randomized study enrolled patients whose disease had not progressed after induction with durvalumab, platinum chemotherapy and etoposide, with PFS and ORR also significantly improved. - No numerical survival data, hazard ratios or safety tables were disclosed, and the full dataset is slated for presentation at an upcoming medical meeting and regulatory submission. - Tarlatamab, a DLL3-directed bispecific T-cell engager already approved in second-line ES-SCLC, could move earlier into the maintenance setting if the benefit is confirmed.
- Navion Neurosciences closed a $10.8 million first seed tranche led by the Angelini Lumira Biosciences Fund to advance precision sodium-channel therapeutics for genetic epilepsy and chronic neuropathic pain. - Proceeds will fund the company's preclinical lead programs and further development of its AI-enabled NaViGATion platform, which integrates AI chemistry, structural biology and ion-channel expertise. - The company aims to improve the therapeutic window of sodium-channel modulation, a limitation that has historically constrained broad-acting agents in epilepsy and pain. - Navion's leadership previously built Cavion, an ion-channel company acquired by Jazz Pharmaceuticals in 2019, and both lead programs remain preclinical.
- The FDA granted accelerated approval to dordaviprone (Modeyso) in August 2025 for recurrent H3 K27M-mutant diffuse midline glioma, the first-ever approved medication for this brain cancer type. - DIPG accounts for 75% to 80% of pediatric brainstem tumors, with 150 to 300 U.S. children diagnosed annually and fewer than 10% surviving two years. - UW-Madison researcher Owen Tamplin uses transparent zebrafish models to study DIPG tumor formation and screen drug combinations, reporting a promising compound called P2. - Grassroots fundraising, including the RunTough for Team Owen event, raised $111,547 for pediatric brain cancer research by September 2025.
- Skye Bioscience will acquire UK-based Redx Pharma via a UK scheme of arrangement, with the combined company trading on Nasdaq as Fibrx Therapeutics and led by Redx's management team. - The transaction is backed by roughly $125 million in concurrent financings, including a $68 million PIPE and a $36 million Redx Series A, with cash expected to fund operations into 2029. - Fibrx will focus on fibrosis, led by RXC008, a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn's disease holding FDA Fast Track designation and an open US IND. - The deal follows Skye's decision to discontinue its Phase IIa CBeyond obesity trial of nimacimab, with pre-transaction Skye shareholders receiving a contingent value right tied to any nimacimab monetization.
- Pliant Therapeutics' FORTIFY Phase 1b trial of PLN-101095 in ICI-refractory solid tumors is enrolling ahead of schedule, with interim data expected in 2027. - Updated Phase 1 biomarker data presented at AACR showed coordinated T-cell reactivation cascade, including increases in IFN-γ, CXCL9, and granzyme-B in all responders. - The company appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its Board of Directors, adding deep oncology drug development and commercialization expertise. - Pliant reported a reduced net loss of $22.4 million for Q2 2026 and holds $159.6 million in cash, sufficient to fund operations into the second half of 2028.
- Jazz Pharmaceuticals announced a definitive agreement to acquire Actio Biosciences for $820 million upfront, with up to $500 million in contingent milestones. - The acquisition centers on ABS-1230, a first-in-class oral small molecule KCNT1 ion channel inhibitor for KCNT1+ epilepsy, a rare genetic disorder with no FDA-approved therapies. - ABS-1230 has demonstrated meaningful seizure reductions in an early proof-of-concept trial and holds FDA Fast Track, Rare Pediatric Disease, Orphan Drug, and RDEP designations. - The ongoing Phase 1b/2a KYRON trial is designed as a registrational study to support a new drug application submission in the United States.
- The global esophageal cancer market across seven major markets was valued at USD 1.3 billion in 2025 and is projected to grow at a 6% CAGR through 2036, according to a DelveInsight report. - Approximately 79,000 incident cases of esophageal cancer were reported across the 7MM in 2025, with the United States accounting for the largest treatment market share. - Emerging therapies including antibody-drug conjugates such as Telisotuzumab adizutecan, bispecific antibodies like Zanidatamab, and next-generation immunotherapies are expected to reshape the treatment landscape. - Recent FDA approvals of durvalumab, pembrolizumab, and tislelizumab in perioperative and frontline settings have expanded immunotherapy options for esophageal cancer patients.
- Biotech stocks have surged over the past year, with the NYSE Arca Biotechnology Index and Nasdaq Biotechnology Index returning more than 56%, outpacing the Nasdaq 100's 29% gain. - Goldman Sachs analysts point to strong fundamentals driven by innovation in cardiovascular disease, cancer, and Alzheimer's, with key data readouts expected in the second half of the year. - The obesity drug market is projected to reach $114 billion globally by 2030, with oral medications expected to comprise 40% of the market and Medicare coverage unlocking further growth. - Large-cap biopharma companies face patent expirations and are actively seeking M&A to fill pipelines, with oncology, immunology, neuroscience, and cardiometabolic health as key areas of interest.
